99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.

[1]  A. Sasikumar,et al.  Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. , 2016, Nuclear medicine and biology.

[2]  P. Stricker,et al.  68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.

[3]  O. Boerman,et al.  Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent , 2016, Theranostics.

[4]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[5]  H. VanBrocklin,et al.  A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. , 2015, Nuclear medicine and biology.

[6]  Nassir Navab,et al.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. , 2015, European Urology.

[7]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[8]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[9]  G. Delost,et al.  Supplementary Table 1 , 2015 .

[10]  S. Vallabhajosula,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer , 2014, The Journal of Nuclear Medicine.

[11]  M. Pomper,et al.  64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer , 2014, Journal of medicinal chemistry.

[12]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  W. Eckelman,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[14]  M. Pillai,et al.  99Mo/(99m)Tc separation: an assessment of technology options. , 2013, Nuclear medicine and biology.

[15]  W. Eckelman,et al.  Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics , 2012 .

[16]  U. Haberkorn,et al.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer , 2012, EJNMMI Research.

[17]  R. Boellaard,et al.  Reproducibility of quantitative (R)-[11C]verapamil studies , 2012, EJNMMI Research.

[18]  Xiaoping Xu,et al.  Radiosynthesis, biodistribution and micro-SPECT imaging study of dendrimer-avidin conjugate. , 2011, Bioorganic & medicinal chemistry.

[19]  M. Schwaiger,et al.  Radionuclide and hybrid imaging of recurrent prostate cancer. , 2011, The Lancet Oncology.

[20]  Xiaoping Xu,et al.  Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates. , 2010, Journal of medicinal chemistry.

[21]  D. Gillatt,et al.  A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[22]  Martin G Pomper,et al.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.

[23]  Philip S Low,et al.  Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. , 2009, Molecular pharmaceutics.

[24]  Y. Igarashi,et al.  Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors. , 2009, Bioorganic & medicinal chemistry letters.

[25]  R. Miralbell,et al.  Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  N. Bander,et al.  Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. , 2007, International journal of oncology.

[27]  F. Fazio,et al.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. , 2007, European urology.

[28]  S. Campbell,et al.  Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[29]  Shuang Liu,et al.  The role of coordination chemistry in the development of target-specific radiopharmaceuticals. , 2004, Chemical Society reviews.

[30]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[31]  B. Sarg,et al.  Preparation via coligand exchange and characterization of [99mTc‐EDDA‐HYNIC‐D‐Phe1,Tyr3]Octreotide (99mTc–EDDA/HYNIC–TOC) , 2003 .

[32]  V. Reuter,et al.  Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. , 2001, Urology.

[33]  Shuang Liu,et al.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. , 1999, Chemical reviews.

[34]  S. Mather,et al.  99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. , 1999, Nuclear medicine and biology.

[35]  V. Paradis,et al.  Molecular expression of PSMA mRNA and protein in primary renal tumors , 1999, International journal of cancer.

[36]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[37]  George L. Wright,et al.  Location of prostate‐specific membrane antigen in the LNCaP prostate carcinoma cell line , 1997, The Prostate.

[38]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[39]  Quintão Ec.  The importance of apolipoproteins in dyslipidemias , 1988 .

[40]  Jianping Zhang,et al.  Radiation dosimetry estimates of [18F]-fluoroacetate based on biodistribution data of rats. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[41]  Freddie C Hamdy,et al.  Screening for prostate cancer: an update. , 2008, European urology.

[42]  M. Schwaiger,et al.  The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  S R J Bott,et al.  Management of recurrent disease after radical prostatectomy , 2004, Prostate Cancer and Prostatic Diseases.

[44]  Richard D. Williams,et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.